Treatment Effect of Recombinant Human Interferon α1b Nebulized Inhalation Combined with Budesonide on Children with Recurrent Upper Respiratory Tract Infection
Objective To analyze the treatment effect of recombinant human interferon α1b nebulized inhalation combined with budesonide on children with recurrent upper respiratory tract infections(RURTI).Methods 90 RURTI children admitted to our hospital from June 2022 to June 2023 were selected and randomly divided into combined group(n=45)and single group(n=45).The single group was treated with pidotimod,while the combined group was treated with recombinant human interferon α1b nebulized inhalation combined with budesonide.The clinical efficacy,symptom disappearance time and adverse reactions were compared between the two groups.Results The total effective rate of the combined group was 93.33%,higher than 75.56%of the single group(P<0.05).The disappearance time of fever,sore throat,cough,and lung rales in the combined group was shorter than that in the single group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Recombinant human interferon α1b nebulized inhalation combined with budesonide in the treatment of RURTI children can improve the clinical efficacy,and shorten the disappearance time of fever,sore throat,cough,and lung rales,with good safety.
Recurrent upper respiratory tract infectionRecombinant human interferonα1bBudesonide
国家科技期刊平台
NSTL
万方数据
